Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HBV
- Sponsor
- Fubing Wang
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- single cell RNA sequencing
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
In summary, with the help of single-cell sequencing technology, this study aims to focus on elucidating the influence of HBV-induced hepatocellular carcinoma cell metabolic changes on microenvironment remodeling. With the help of hepatocellular carcinoma microenvironment changes, this study provide a more accurate diagnosis and treatment method for HBV-induced hepatocellular carcinoma.
Investigators
Fubing Wang
Dr.Prof.
Zhongnan Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients with primary liver cancer (hepatocellular carcinoma (HCC)), with evidence of histological or cytological diagnosis, or with HCC meeting conventional clinical diagnostic criteria.
- •Both sexes, aged 18-80 years old
- •The results of HBVDNA test were in line with the inclusion criteria
- •The patient had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST V1.1)
- •Agreed to comply with the study protocol for treatment and follow-up, agreed to provide clinicopathological and follow-up data required by the study, and agreed to use the study data for subsequent research and product development
Exclusion Criteria
- •Other malignant tumors;
- •Patients with severe organic diseases do not meet the requirements of infectious liver cancer in this study;
- •Suffering from mental illness cannot guarantee the compliance of this study;
- •Previous recipients of any cell or organ transplantation;
- •Received local regional liver therapy (including various ablations, percutaneous ethanol or acetic acid injections, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization plus embolization) within 14 days prior to study treatment initiation.
Outcomes
Primary Outcomes
single cell RNA sequencing
Time Frame: within 4 hours after the sample was submitted for examination
10x genomics chromium 3' sequencing
Biochemical index detection
Time Frame: within 4 hours after the sample was submitted for examination
HbsAg (IU/mL) \\HbsAb (mIU/mL)\\HbeAg\\HbeAb\\HbcAb
HBV DNA copy number
Time Frame: within 24 hours after the sample was submitted for examination
HBV DNA (IU/mL)